Background {#Sec1}
==========

Penile carcinoma (PeCa) is a globally rare neoplasia that mainly affects men between 50 and 70 years of age. The incidence reported in 2012 was 26,000 new cases worldwide \[[@CR1]\]. PeCa is most frequent in developing countries, particularly in regions of Africa, South America and Asia, where PeCa may represent up to 10% of all tumors in men \[[@CR2]\].

Ninety-five percent of all PeCa cases are of the squamous type, originating in the internal mucosa of the glans, coronal sulcus or skin. The current histopathological classification from the WHO regarding the human papillomavirus (HPV) states that among the histological subtypes of squamous cell carcinoma not related to HPV are usual, pseudohyperplastic and pseudoglandular, verrucous, papillary and adenosquamous. Other types not associated with HPV are sarcomatoid and mixed \[[@CR3], [@CR4]\]. The risk factors involved in these subtypes are chronic inflammation, phimosis, lichen sclerosus and lichen planus \[[@CR5]\].

Between 30 and 50% of all cases of invasive PeCa are related to HPV, and the main histological subtypes are basaloid and warty. Warty carcinoma includes classical, clear cell carcinoma and warty-basaloid. The basaloid type can be subdivided into the classic and papillary subtypes. Basaloid carcinomas have a high rate of regional metastasis, while warty carcinomas are rarely metastatic. Other less frequent tumors are lymphoepithelioma and medullary squamous cell carcinoma \[[@CR1], [@CR3]\].

HPV16 is the most frequent genotype in PeCa throughout the world, regardless of geographic region. However, the order of frequency of other genotypes varies with region. For example, HPV genotypes 30, 33 and 52 are more present in Africa; 6, 11 and 33 in America; 33, 35 and 45 in Asia; and 52, 6 and 33 in Europe. It is interesting to note that low-risk genotypes 6 and 11 are regularly detected in PeCa. In fact, a recent meta-analysis reported that HPV16 was the second most common genotype in PeCa and the third most common genotype as a single infection after HPV18 \[[@CR6]--[@CR8]\].

Current studies have emphasized that the detection of viral DNA is not sufficient to establish a causal relationship between HPV and cancer. Thus, other surrogate biomarkers of transformation induced by HPV infection, such as overexpression of P16INK4A, should also be evaluated, as well as the presence of viral activity by detection of expression of viral oncoproteins, such as E6\*I \[[@CR9], [@CR10]\].

Next-generation sequencing has shown a broad spectrum of HPV in both mucosal and skin epithelium, where a wide variety of genotypes of alpha, beta and gamma genera have been identified \[[@CR11]\]. Nevertheless, the IARC only includes 12 genotypes as type 1 carcinogens at present, and the oncogenic capacity of other genotypes is currently being assessed according to epidemiology and molecular alterations that are characteristic of HPV-induced carcinogenesis \[[@CR10]\].

In Mexico, there are several reports on the frequency and diversity of HPV, mainly in cervical cancer \[[@CR12]--[@CR14]\]. However, studies on PeCa and HPV are scarce. López et al. identified HPV in 78% of PeCa cases using GP primers, finding that the most prevalent genotypes were HPV 16, 31, and 11 \[[@CR15]\]. Other works have addressed the presence of HPV in penile samples from the general population, where HPV was identified in 62% of the cases \[[@CR16]\]. In a study analyzing penile intraepithelial lesions, HPV was detected in all cases, 80% of which were positive for multiple genotypes \[[@CR17]\]. To contribute to the knowledge of the etiopathogenesis of PeCa in Mexico, we evaluated a group of 60 patients with a diagnosis of PeCa and determined the frequency of HPV, the genotypes of HPV, and the presence of multiple HPV genotypes, and expression of P16INK4A as a surrogate marker, as well as the clinical and histopathological characteristics, of PeCa according to the WHO 2016 classification.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Sixty cases of penile carcinoma were collected from pathology archives of the Oncology Hospital, National Medical Center S XXI, Instituto Mexicano del Seguro Social (IMSS). The project was approved by The Research and Ethics Committee (R-2014-3602-26). An expert pathologist revised the histopathological description of each case according to the 2016 WHO classification of penile cancer \[[@CR4]\]. Tissues were selected for tissue microarray (TMA) construction and DNA extraction.

HPV genotyping {#Sec4}
--------------

Paraffin-embedded tissues were sectioned for DNA extraction using the Wizard FFPE Kit from a ReliaPrep™ FFPE gDNA Miniprep System Wizard (Promega) kit. HPV detection was carried out using an INNO-LiPA® HPV Genotyping Extra Test (Innogenetics now Fujirebio) commercial kit. This kit allows the simultaneous detection of 28 viral types classified according to the IARC as follows: Group I: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; Group 2A: VPH68; Group 2B: HPV26, 53, 66, 69, 70, 73, 82; Group 3: HPV6 and 11; and others: HPV 40, 43, 44, 54, 71, 74. The technique is based on PCR amplification with SPF10 primers and reverse line hybridization with specific probes for the mentioned genotypes. The process was performed on an Autolipa™ 48 device, and the results were interpreted by Liras® software for LIPA HPV V2. Only samples with a positive reaction in the HLA-DPB1 control were included in the analysis. Any genotype not clearly present according to the results issued by the software was not considered in the analysis.

Tissue microarray and P16INK4A immunohistochemistry {#Sec5}
---------------------------------------------------

Representative tumor areas were selected for the construction of a tissue microarray (TMA) with an Advance Tissue Array™ ATA-100 instrument (Chemicon International). Two or three 1 mm diameter tissue cores from each of the samples were placed in a receptor paraffin block. Control tissues from cervical cancer and tonsil tissue were included in the TMA. Histological, 4 μm thick sections were mounted on adhesive slides. The detection of P16INK4A was performed by immunohistochemistry with a CINtec® histology antibody (E6H4 clone) in an automated Benchmark Autostainer™ device (Ventana Medical Systems Inc.). The reaction was developed using an UltraView™ Universal DAB kit (Ventana Medical Systems Inc.). Tissues were stained with hematoxylin and dehydrated and mounted with synthetic resin.

Positivity for P16INK4A was considered when more than 70% of the cells presented a strong and diffuse, nuclear and/or cytoplasmic staining pattern, according to the Larsen study \[[@CR18]\]. For those cases that were HPV-DNA positive and P16INK4A-negative in TMA, a new immunohistochemical test was performed in the complete tissue block.

Statistical analysis {#Sec6}
--------------------

Data were processed with the PASW Statistics™ version 18.0 (IBM Corporation, Somers NY) statistical package. Qualitative variables were described as frequencies and percentages. The association between clinicopathological variables was evaluated using the chi-squared test and Fisher's exact test. A logistic regression model was used to obtain the contribution of HPV genotypes and morphological classification. Values of p below 0.05 were considered statistically significant.

Results {#Sec7}
=======

Sixty cases diagnosed as squamous cell carcinoma of the penis were obtained from pathology archives. Patients ranged from 24 to 95 years of age, with a mean of 62.3 years ±16.4. Patients below the age of 45 years comprised 13.3% of the total. The most common anatomic site of origin was the glans in 59% of the cases, while 20% of the cases involved two or more origin sites (multifocal). Primary treatment performed on 70% of the patients was total penectomy, while the remaining 30% underwent a partial procedure. Regarding the size of the tumors, 63.5% were larger than 5 cm at the time of diagnosis. Clinical stages I and II were present in 34.2% of the patients, and stages III and IV were present in 65.7% (Table [1](#Tab1){ref-type="table"}). Regarding histological types, 75% of the cases were non-HPV related; among them, the most common variant was squamous cell carcinoma of the usual type (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Table 1Descriptive clinical characteristics of penile cancerCharacteristicsTotalHPV PositiveHPV MGP16INK4A+*n* = 60%*n* = 5655%n = 33%*n* = 5530.9%Age diagnosis  ≤ 45813.34/757.100.02/633.3 46--551321.75/1241.7120.00/120.0 56--651118.35/1050.0360.03/1030.0 66--751220.08/1266.7112.54/1233.3  ≥ 761423.010/1376.9550.07/1353.8 ¿?23.31/250.000.01/250.0Tobacco Yes1637.27/1546.7457.13/1520.0 No2762.816/2564.0531.38/2433.3Alcohol Yes1023.35/955.65100.03/933.3 No3376.718/3158.1422.28/3026.7*p* = 0.0037Anatomical region Corpus24.11/250.01100.01/250.0 Glans2959.215/755.6320.04/615.4 Prepuce612.22/633.32100.02/633.3 Coronal surcus24.12/2100.000.01/250.0 Multifocal1020.47/1070.0342.95/1050.0Tumoral size  \< 5 cm1536.610/1566.7440.05/1533.3 5--10 cm1741.510/1662.5110.05/1533.3  \> 10 cm922.04/757.14100.02/825.0Clinical Stage I617.15/683.3240.01/520.0 II617.13/475.0133.32/540.0 III1131.47/1163.6228.63/1030.0 IV1234.35/1145.5120.02/1118.2*HPV MG* HPV Multiple Genotypes Fig. 1Histology classification of penile squamous cell carcinoma. The classification was done according to 2016 WHO Table 2HPV presence and P16INK4A expression in penile squamous cell carcinomasTotalHPV-HPV+HPV MGP6INK4A+P16INK4A-n%n%n%n%n%n%HPV-non-related carcinoma4575.01741.52458.5520.81127.52972.5 Squamous cell carcinoma usual3863.31542.92057.1420.01132.42367.6 Verrucous46.7125.0375.000.000.04100.0 Papillary NOS11.71100.000.000.000.01100.0 Sarcomatoid11.7N.D.N.D.N.D.N.D.N.D. Mixed11.700.01100.01100.000.01100.0HPV-related penile carcinoma1525.0640.0960.0555.6640.0960.0 Basaloid711.3228.6571.4360.0571.4228.6 Warty813.3450.0450.0250.0112.5787.5Histologycal grade Grade 12745.01661.51038.5330.0312.52187.5 Grade 22541.7730.41669.6425.0937.51562.5 Grade 383.300.07100.0342.9571.4228.6*p* = 0.0053*p* = 0.0079The histological classification was carried out according to the WHO 2016 criteria. The HPV detection was performed using Inno-Lipa, only 56 cases were valid. Regarding P16INK4A, the evaluation was performed in 55 cases. Statistically significant differences are indicated *p* \< 0.05 (chi square test)*HPV MG* HPV multiple genotypes, *N.D* Not determinate

Four cases were excluded because the control gene was not amplified, leaving 56 cases. Of these, 58.9% (*n* = 33) were HPV positive, of which 69.7% (*n* = 23) had only one viral genotype (single genotype) and 30.3% (*n* = 10) had more than one viral type (multiple genotypes) (Fig. [2](#Fig2){ref-type="fig"}a). Among the sixteen different viral genotypes detected, HPV16 had the highest frequency (42.9%) (Fig. [2](#Fig2){ref-type="fig"}b), followed by HPV52 (7.1%) and HPV18 (5.4%). The most frequent low-risk genotype was HPV11 (3.6%). These data reflect only the genotypes accurately identified by the test \[[@CR19]\]. The WHO morphological classification (HPV-related) was not associated with HPV-DNA molecular detection (*p* = 0.9). Fig. 2Human papillomavirus DNA in penile carcinoma. **a** proportion of HPV negative cases, HPV single genotype, and HPV multiple genotypes. **b** The frequency of HPV genotypes and carcinogenic classification according to the IARC. \* The possible presence of HPV is not ruled out

Nevertheless, because of the detection method used (INNO-LiPA®), the presence of HPV52 and HPV54 with other high-risk genotypes, such as 16, 31 and 33, could not be ruled out, as well as HPV 39 with HPV 18. Of the HPV16 positive cases, 15 were identified in single infections, and 7 were identified with other genotypes, such as HPV 18, 66, 33, 45 and 52. It is important to note that HPV18 was only found together with other high-risk genotypes, such as HPV 16, 45 and 51.

The presence of P16INK4A was analyzed in 55 samples. Of these, 17 (30.9%) were considered positive, as they presented a pattern of intense, diffuse staining in more than 70% of the tissue analyzed (Fig. [3](#Fig3){ref-type="fig"}). All samples positive for P16INK4A also presented with HR-HPV. However, of all the samples positive for HR-HPV, only 60.7% were positive for P16INK4A (11 cases positive for HR-HPV were negative for P16INK4A). In these cases, the immunohistochemical test was repeated in complete tissue blocks. All of them were negative (not shown). Regarding histological characteristics, the expression of P16INK4A and the presence of HPV were significantly associated with the degree of differentiation (*p* \< 0.05) (Table [1](#Tab1){ref-type="table"}). Fig. 3Expression of P16INK4A in penile carcinoma. **a** and **b** correspond to an epidermoid case of the usual type moderately differentiated with HPV 31 and positive to P16INKA. **c** and **d**, poorly differentiated basaloid variant epidermoid carcinoma, positive for HPV35 and P16INK4A. **e** and **f**, usual moderately differentiated carcinoma negative to HPV with low expression of P16INK4A. **g** and **h**, basaloid carcinoma moderately differentiated negative to HPV and P16INK4A

Discussion {#Sec8}
==========

In the present study of 60 cases of squamous PeCa, although 45 (75%) were histologically classified as non-HPV-related, 33 of 56 cases tested (58.9%) were positive for HPV-DNA. A recent meta-analysis showed that, on average, 50.8% of PeCa cases presented with HPV \[[@CR8]\]. According to ICO reports, the frequency of HPV-DNA in PeCa oscillates between 87% in South Africa and 13.3% in Asia \[[@CR6]\], indicating differences with respect to geographical regions. Interestingly, our work is in contrast with a previous report from Mexico, in which 78% of cases were identified as positive by using GP5/GP6+ primers \[[@CR15]\]. It is noteworthy that, in comparison, the INNO-LiPA® method is considered a more sensitive technique \[[@CR20]\].

In the WHO classification of PeCa, the "usual type" variant is categorized as not related to HPV \[[@CR3], [@CR4]\]. However, we did not find differences between the presence of HPV-DNA and the histological classification of "HPV-related". Because in many cases only one representative block was evaluated, it is possible that the mixed variant may not have been identified in some cases. In this study, all cancers with P16INK4A overexpression had HPV-DNA detected. However, not all cases positive for HPV-DNA were positive for P16INK4A. Some evidence suggests that the detection of viral DNA is not sufficient for the etiological attribution of HPV-related cance; but is necessary to identify transcriptional activity or molecular signature of HPV-induced carcinogenesis \[[@CR9], [@CR10]\].

Worldwide, the most frequent genotypes reported in PeCa are HPV16, 6, 33, 35, 45 and 52 \[6\]. In our work, we identified the following genotypes in descending order: 16, 52, 18, 45, 31 and 11. The distribution of high-risk genotypes different from HPV16 varies with geography and anatomical site \[[@CR6], [@CR21]\]. According to several reports, HPV18 is not found within the five most frequent genotypes in PeCa, either globally or by continent \[[@CR6]\]. In fact, in some studies, such as the one by de Andrade et al., HPV18 was not detected at all \[[@CR22]\]. The differences may be because HPV18 preferentially infects and transforms columnar epithelial tissue, such as in cervical adenocarcinomas \[[@CR23]\]. Interestingly, Senba et al. reported HPV18 as the most common genotype in PeCa in Thailand (55%) \[[@CR24]\]. A high frequency of HPV18 in cervical cancer, particularly in adenocarcinoma (53%), has also been reported in Thailand \[[@CR25]\]. In the present study, HPV18 was the third most frequent genotype, although we only found it together with other high-risk genotypes.

The presence of multiple HPV genotypes has been explored mainly in cervical cancer and its precursor lesions \[[@CR14], [@CR26]--[@CR28]\]. Some studies have suggested an association between an increase in the risk of cervical disease and the cumulative number of HPV genotypes \[[@CR28]\], whereas other studies have reported that the number of genotypes present has no additive effect on the risk of precursor lesions \[[@CR26]\]. To date, only a few studies have analyzed the presence of multiple HPV genotypes in PeCa. Fernandez et al. \[[@CR29]\] recently reported that 53% of penile intraepithelial neoplasia (PeIN) presented multiple HPV genotypes. Rantshabeng et al. reported a higher frequency of multiple HPV genotypes in HIV-positive patients compared to HIV-negative patients with anogenital cancer, including penile cancer \[[@CR30]\]. A high prevalence of multiple HPV genotypes (59%) has also been reported in the exfoliative cytology (urethra, penis, scrotum anus) of men referred for evaluation of genital lesions such as warts and sexually transmitted infections, finding up to 9 viral genotypes \[[@CR31]\]. Afonso et al. identified multiple genotypes in 23% of HPV-positive samples of PeCa, where HPV16 was found in almost half of the samples \[[@CR32]\]. In our study, we identified a similar proportion of multiple genotypes (30%) in HPV-positive cases. To date, however, the role of multiple genotypes in the development and progression of PeCa has not been addressed in detail.

Regarding the patient's age, we found that 57% of patients under 45 years were HPV positive, and all of them had a single HPV16 infection. In contrast, 76% of older patients (\> 76 years) were HPV positive, and only one half of them presented a single genotype (HPV16 or HPV35). These data suggest a relationship between genotype and age, possibly due to fast progression caused by a variety of events such as chromosomic instability and viral integration associated with the oncogenic capacities of E6 and E7 \[[@CR33]--[@CR36]\]. Although one of the limitations in the present work is the number of samples analyzed, the data show a tendency that associates age with the presence of multiple genotypes. Patient grade 3 differentiation shows an association with HPV-positive tumors, in concordance with a previous report \[[@CR37]\].

Although P16INK4A has been defined as a surrogate marker for high-risk HPV-induced transformation, differences have been observed in the concordance between HPV presence and P16INK4A expression \[[@CR29], [@CR38]\]. Some studies have reported approximately 10% of PeIN cases that are HR-HPV positive and negative for P16INK4A \[[@CR29]\] and up to 50% of cases in PeCa \[[@CR22]\]. Some explanations attribute this to a transitory infection of HPV, unrelated to the carcinogenic process. Another cause may be the epigenetic mechanisms of the inactivation of *CDNK2A*, as well as loss of heterozygosity \[[@CR39]\]. Therefore, the detection of viral transcripts and surrogated markers can be used to define cases attributed to HR-HPV \[[@CR40]\].

Conclusions {#Sec9}
===========

In our study, HPV was detected in almost 60% of PeCa cases, although three quarters were classified as non-HPV-related tumors. HPV16 was found to be the most frequent genotype present, followed by HPV52, 33, 35, and 39. Most of these could be prevented by nonavalent HPV vaccination. The role of multiple HPV genotypes in PeCa is of interest. The etiological attribution to HPV in PeCa may be stratified with more certainty by using biomarkers such as viral oncoprotein mRNA and surrogate markers such as P16INK4A.
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